[Combination Therapy with Radiation, Temozolomide, and Bevacizumab after Partial Tumor Removal in Glioblastoma Patients with Low Performance Status].

Abstract

INTRODUCTION:

It is unclear whether or not bevacizumab(Bev)has a curative ability in newly diagnosed glioblastoma(GBM) patients with low Karnofsky performance status(KPS).

MATERIALS AND METHODS:

Four of 14 patients with newly diagnosed GBM received combination therapy with extended local radiation, temozolomide(TMZ), and Bev after partialremovalor biopsy of the tumor.

RESULTS:

The average patient age was 77.2 years(range 67-85)and the male-to-female ratio was 1:3. In all cases, magnetic resonance imaging showed that combination therapy decreased tumor volume and peritumoral edema volume. The therapy was successfully administered to 3 patients without decreasing their KPS. However, 1 patient with seeding lesions dropped out of therapy because of deteriorating consciousness and decreasing KPS.

DISCUSSION:

Subgroup analysis in a randomized control study(AVAglio)showed that patients with a PS score of 1-2(corresponding to a KPS score of 60-80)tended to have prolonged survival after Bev treatment compared with those with a PS score of 0(corresponding to a KPS score of 90-100). In the present study, radiochemotherapy with Bev decreased lesion and edema volumes in all patients, and led to maintained or improved KPS in 3 patients. These results suggest that the treatment is potentially effective for patients with newly diagnosed GBM and lower KPS.

• Authors: Junzo Nakao, Eiichi Ishikawa, Masahide Matsuda, Tetsuya Yamamoto, Shingo Takano, Akira Matsumura
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 44 Issue 6 Pg. 495-500 (Jun 2017) ISSN: 0385-0684 [Print] Japan
• PMID: 28698441 (Publication Type: Journal Article)

Chemical References

• Bevacizumab
• Dacarbazine
• Temozolomide

Topics

• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab (administration & dosage)
• Chemoradiotherapy
• Dacarbazine (administration & dosage, analogs & derivatives)
• Female
• Glioblastoma (therapy)
• Humans
• Male
• Temozolomide
• Treatment Outcome